282 related articles for article (PubMed ID: 23580068)
21. Identification and Management of
Pal T; Brzosowicz J; Valladares A; Wiesner GL; Laronga C
South Med J; 2017 Oct; 110(10):643-648. PubMed ID: 28973705
[TBL] [Abstract][Full Text] [Related]
22. TP53 germline mutations in adult patients with adrenocortical carcinoma.
Herrmann LJ; Heinze B; Fassnacht M; Willenberg HS; Quinkler M; Reisch N; Zink M; Allolio B; Hahner S
J Clin Endocrinol Metab; 2012 Mar; 97(3):E476-85. PubMed ID: 22170717
[TBL] [Abstract][Full Text] [Related]
23. Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study).
Packwood K; Martland G; Sommerlad M; Shaw E; Moutasim K; Thomas G; Bateman AC; Jones L; Haywood L; Evans DG; Birch JM; Alsalmi OA; Henderson A; Poplawski N; Eccles DM
J Pathol Clin Res; 2019 Jul; 5(3):189-198. PubMed ID: 31041842
[TBL] [Abstract][Full Text] [Related]
24. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.
Fortuno C; James PA; Spurdle AB
Hum Mutat; 2018 Dec; 39(12):1764-1773. PubMed ID: 30240537
[TBL] [Abstract][Full Text] [Related]
25. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.
Mai PL; Best AF; Peters JA; DeCastro RM; Khincha PP; Loud JT; Bremer RC; Rosenberg PS; Savage SA
Cancer; 2016 Dec; 122(23):3673-3681. PubMed ID: 27496084
[TBL] [Abstract][Full Text] [Related]
26. Germline TP53 mutational spectrum in French Canadians with breast cancer.
Arcand SL; Akbari MR; Mes-Masson AM; Provencher D; Foulkes WD; Narod SA; Tonin PN
BMC Med Genet; 2015 Apr; 16():24. PubMed ID: 25925845
[TBL] [Abstract][Full Text] [Related]
27. Clinical and molecular characterization of patients fulfilling Chompret criteria for Li-Fraumeni syndrome in Southern Brazil.
Matzenbacher Bittar C; de Araújo Rocha YM; Vieira IA; Rosset C; Andreis TF; Sartor ITS; Artigalás O; Netto CBO; Alemar B; Macedo GS; Ashton-Prolla P
PLoS One; 2021; 16(9):e0251639. PubMed ID: 34529667
[TBL] [Abstract][Full Text] [Related]
28. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.
Kumamoto T; Yamazaki F; Nakano Y; Tamura C; Tashiro S; Hattori H; Nakagawara A; Tsunematsu Y
Int J Clin Oncol; 2021 Dec; 26(12):2161-2178. PubMed ID: 34633580
[TBL] [Abstract][Full Text] [Related]
29. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV
J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190
[TBL] [Abstract][Full Text] [Related]
30. TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients.
Hahn EC; Bittar CM; Vianna FSL; Netto CBO; Biazús JV; Cericatto R; Cavalheiro JA; de Melo MP; Menke CH; Rabin E; Leistner-Segal S; Ashton-Prolla P
PLoS One; 2018; 13(12):e0209934. PubMed ID: 30596752
[TBL] [Abstract][Full Text] [Related]
31. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome.
Kamihara J; Rana HQ; Garber JE
Hum Mutat; 2014 Jun; 35(6):654-62. PubMed ID: 24706533
[TBL] [Abstract][Full Text] [Related]
32. Clinical implications of germline mutations in breast cancer: TP53.
Schon K; Tischkowitz M
Breast Cancer Res Treat; 2018 Jan; 167(2):417-423. PubMed ID: 29039119
[TBL] [Abstract][Full Text] [Related]
33. Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients.
Kwong A; Shin VY; Ho CYS; Au CH; Slavin TP; Weitzel JN; Chan TL; Ma ESK
BMC Cancer; 2020 Nov; 20(1):1053. PubMed ID: 33138793
[TBL] [Abstract][Full Text] [Related]
34. TP53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge.
Grill S; Ramser J; Hellebrand H; Pfarr N; Boxberg M; Brambs C; Ditsch N; Meindl A; Groß E; Meitinger T; Kiechle M; Quante AS
Arch Gynecol Obstet; 2021 Jun; 303(6):1557-1567. PubMed ID: 33245408
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of germline TP53 mutations and history of Li-Fraumeni syndrome in families with childhood adrenocortical tumors, choroid plexus tumors, and rhabdomyosarcoma: a population-based survey.
Magnusson S; Gisselsson D; Wiebe T; Kristoffersson U; Borg Å; Olsson H
Pediatr Blood Cancer; 2012 Nov; 59(5):846-53. PubMed ID: 22653678
[TBL] [Abstract][Full Text] [Related]
36. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
[TBL] [Abstract][Full Text] [Related]
37. The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30.
Ginsburg OM; Akbari MR; Aziz Z; Young R; Lynch H; Ghadirian P; Robidoux A; Londono J; Vasquez G; Gomes M; Costa MM; Dimitrakakis C; Gutierrez G; Pilarski R; Royer R; Narod SA
Fam Cancer; 2009; 8(4):563-7. PubMed ID: 19714488
[TBL] [Abstract][Full Text] [Related]
38. Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing.
Rana HQ; Gelman R; LaDuca H; McFarland R; Dalton E; Thompson J; Speare V; Dolinsky JS; Chao EC; Garber JE
J Natl Cancer Inst; 2018 Aug; 110(8):863-870. PubMed ID: 29529297
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.
Ponti F; Corsini S; Gnoli M; Pedrini E; Mordenti M; Sangiorgi L
Fam Cancer; 2016 Oct; 15(4):635-43. PubMed ID: 26956143
[TBL] [Abstract][Full Text] [Related]
40. Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome).
Petry V; Bonadio RC; Cagnacci AQC; Senna LAL; Campos RDNG; Cotti GC; Hoff PM; Fragoso MCBV; Estevez-Diz MDP
Fam Cancer; 2020 Jan; 19(1):47-53. PubMed ID: 31748977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
